Status
Conditions
Treatments
About
The purpose of this study is to demonstrate the safety and 12-month effectiveness of the BWI OMNYPULSE™ pulsed field ablation (PFA) platform for pulmonary vein isolation (PVI) in the treatment of participants with symptomatic paroxysmal atrial fibrillation (PAF), an irregular heart rate that causes abnormal blood flow.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosed with symptomatic paroxysmal AF with:
Failed at least one Class I or Class III antiarrhythmic drug
Willing and capable to provide consent
Able and willing to comply with all pre-, post- and follow-up testing and requirements
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
440 participants in 1 patient group
Loading...
Central trial contact
Study Contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal